Results 11 to 20 of about 8,062 (139)

Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond [PDF]

CNS Drugs, 2016
The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been demonstrated to be involved in vesicle trafficking and exocytosis, processes crucial for neurotransmission.
Rafal M Kaminski, Wolfgang Loscher, Michel Gillard   +2 more
exaly   +5 more sources

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging [PDF]

JAMA Neurology, 2018
Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. Synaptic vesicle glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses and ...
Nabeel Nabulsi, Takuya Toyonaga, Jim R Ropchan   +2 more
exaly   +4 more sources

Psilocybin’s effect on human brain synaptic plasticity [PDF]

Translational Psychiatry
Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmental context remain unclear.
Annette Johansen, Pontus Plavén-Sigray, Martin K. Madsen, Anna Søndergaard, Catharina Messel, Maria Geisler, Arafat Nasser, Drummond E-W. McCulloch, Vincent Beliveau, Alexandra Vassilieva, Anton Lund, Szabolcs Lehel, Brice Ozenne, Dea S. Stenbæk, Patrick M. Fisher, Claus Svarer, Gitte M. Knudsen   +16 more
doaj   +2 more sources

Synaptic loss in alcohol use disorder: clinical and mechanistic insights from a PET imaging study [PDF]

The Journal of Clinical Investigation
Alcohol use disorder (AUD) is linked with changes in brain structure and function, with robust evidence for neurodegenerative changes, including synaptic loss in preclinical models.
Sarah K. Royse, Rajesh Narendran
doaj   +2 more sources

Fully Automated Azeotropic Drying-Free Synthesis of [¹⁸F]SynVesT-1 via Copper-Mediated Fluorination Using the Trasis All-in-One Module [PDF]

Molecules
Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane protein expressed in presynaptic vesicles. Positron emission tomography (PET) imaging of SV2A provides an in vivo measure of synaptic density and has broad applications in the study of ...
Falguni Basuli, Jianfeng Shi, Xiang Zhang, Rolf E. Swenson   +3 more
doaj   +2 more sources

Dose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks. [PDF]

Phys Med Biol, 2023
Abstract Objective . Reducing dose in positron emission tomography (PET) imaging increases noise in reconstructed dynamic frames, which inevitably results in higher noise and possible bias in subsequently estimated images of kinetic parameters than those estimated in the standard dose case.
Li A, Yang B, Naganawa M, Fontaine K, Toyonaga T, Carson RE, Tang J.   +6 more
europepmc   +3 more sources

Altered lipid peroxidation, perineuronal net and oligodendrocyte markers in the frontal cortex of a dual-hit neurodevelopmental model support its relevance to schizophrenia [PDF]

Frontiers in Cellular Neuroscience
IntroductionThe pathogenesis of schizophrenia begins in early neurodevelopment and leads to an array of frontal cortical deficits. They include redox dysregulation, white matter perturbation, loss of perineuronal nets (PNNs) and reduced synaptic density.
Victoria Esuaikoh, Sarah Ibegbulam, Alistair Cook, Bianca McFarland, Nora Nunnington, Ambalangoda Perera, Jingjing Feng, Jennifer A. Cale, Madeleine V. King   +8 more
doaj   +2 more sources

Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery [PDF]

Biomedicines
Major depressive disorder remains a leading cause of disability, and decades of monoamine-centered pharmacology have yielded delayed and often incomplete relief.
Masaru Tanaka
doaj   +2 more sources

Increased Expression of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Brain of Chronic Diabetic Rats. [PDF]

Synapse
ABSTRACTAim/hypothesisDiabetes mellitus has been reported to be a risk factor for cognitive dysfunction, depression, stroke, and seizures. Diabetic pathology is believed to interfere with synaptic plasticity. Synaptic vesicle glycoprotein 2A (SV2A) is a presynaptic vesicular protein and a popular synaptic density imaging marker.
Pazarlar BA, Egilmez CB, Oyar EÖ, Mikkelsen JD.   +3 more
europepmc   +4 more sources

First-in-Human Evaluation of ¹⁸F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. [PDF]

J Nucl Med, 2021
The use of synaptic vesicle glycoprotein 2A radiotracers with PET imaging could provide a way to measure synaptic density quantitatively in living humans. 11C-UCB-J ((R)-1-((3-(11C-methyl-11C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one), previously developed and assessed in nonhuman primates and humans, showed excellent kinetic ...
Naganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE.   +12 more
europepmc   +4 more sources